bluuebunny/crossref_metadata_2025_split huggingface dataset:
Induction of plasmacytoid and hairy cell features by phorbol esters (TPA) in B‐lymphoma cells: Attempted correlation with disease activity
Authors: Gazitt Yair , Leizerowitz Rachel , Polliack Aaron 
Published: February 2007

AbstractMononuclear cells concentrated from the blood of 16 non‐Hodgkin's lymphoma (NHL) patients in the leukemic phase, were exposed to 10 ng/ml of TPA in an attempt to induce differentiation. Immunoglobulin (Ig) secretion, surface markers (SmIg, GP‐70), tartrate resistant acid phosphatase (TRAP) and surface features were followed for up to six days in vitro. TPA induced ‘hairy cell’ like features in NHL cells as defined by cell morphology, ultrastructure, cell surface markers and the presence of TRAP. Unlike the results obtained in patients with CLL, cells from different patients at the same stage of disease reacted in a similar way. Differences were evident between NHL mononuclear cells obtained from patients in partial remission and active disease when compared with those derived from patients in complete remission. In the former group, NHL cells were maximally induced by TPA to secrete Ig and higher proportions of TRAP positive cells. In addition hairy cell features as seen by light and scanning electron microscopy were also more pronounced. TPA also induced the maximal expression of SmIg and GP‐70 in cells derived from patients in this group. Patients with NHL in leukemic phase in complete remission did not express surface membrane GP‐70 before or after TPA treatment while SmIg was expressed to some degree before TPA treatment and further induced following treatment with TPA. GP‐70 appears to be a more reliable marker for follow‐up of NHL patients than any other marker studied here.
Management of localized non‐Hodgkin's lymphoma: The experience at St. Bartholomew's hospital 1972–1985
Authors: Richards M. A. , Gregory W. M. , Hall P. A. , Dhaliwal H. S. , Fernandez J. , Stansfeld A. G. , Jones A. E. , Lister T. A. 
Published: February 2007

AbstractA retrospective study of 202 patients with clinical stage I and II non‐Hodgkin's lymphoma managed at St. Bartholomew's Hospital between 1972 and 1985 was conducted. Patients were treated either with radiotherapy alone, radiotherapy and adjuvant chemotherapy, or chemotherapy (with or without adjuvant radiotherapy). At the onset of the study it was intended that all patients with localized NHL should be treated with involved field radiotherapy and adjuvant ‘CVP’. As it became apparent that this was inadequate for some patients and too toxic for others a flexible approach was later adopted. Treatment selection depended on age, volume, distribution of disease and histological subtype.The actuarial 5 year overall survival for the whole group was 70 per cent. Death from lymphoma after 5 years was very rare. Increasing age and high grade histology were highly significant adverse prognostic factors by multivariate analysis. The results for patients with high grade and low grade histology were therefore analysed separately, as was the outcome for patients presenting with either gastrointestinal or skin lymphomas.During the latter part of the study period intensive chemotherapy was given as the initial treatment to patients with high grade histology and bulky, or stage II disease. Twenty out of 24 patients so treated achieved complete remission and only one has relapsed to date. These results are encouraging and probably explain the absence of a difference in prognosis between patients with stage I and IE disease and those with stage II and IIE disease observed over the whole period of the study.Remission was achieved in the overwhelming majority of patients with low grade histology for whom radiotherapy was selected as primary therapy. Duration of remission was better in patients who received adjuvant chemotherapy than in those treated with radiation alone, but no difference in overall survival was observed between these groups. Neither stage nor the presence of a follicular histological pattern correlated with prolonged survival in patients with low grade histology.
Lymphoplasmacytoid and small cell centrocytic non‐Hodgkin's lymphoma—A retrospective analysis from St Bartholomew's hospital 1972–1986
Authors: Richards M. A. , Hall P. A. , Gregory W. M. , Dhaliwal H. S. , Stansfeld A. G. , Amess J. A. L. , Lister T. A. 
Published: February 2007

AbstractLymphoplasmacytoid (1pc) and small cell centrocytic (scc) lymphoma are the two major sub‐types of diffuse low grade non‐Hodgkin's Lymphoma (NHL) within the Kiel classification. The presentation features and outcome for all 112 patients with these diagnoses (60 lpc, 52 scc) managed at St Bartholomew's Hospital between 1972 and 1986 are presented. The outcome for these patients is compared with that for patients with follicular and high grade lymphomas managed at this hospital during the same period.Nineteen of the 112 patients had localized (stages I–IIE) disease. In 18 of these cases the primary site of disease was extranodal, the gastrointestinal tract being involved in 12 cases. The survival for patients with localized disease was excellent. Eighteen are currently alive with median follow‐up of 8 years.Ninety‐three patients had advanced disease. A high incidence of splenomegaly, hepatomegaly, bone marrow and peripheral blood involvement was observed in both histological subgroups. A monoclonal paraprotein band was detected in the serum of nearly 50 per cent of patients with advanced lpc lymphoma.Patients with advanced disease were treated with either chlorambucil or cyclophosphamide, vincristine and prednisolone (CVP). The outcome was similar for both histological groups.Survival for these patients was poor (median 40 months) with less than 20 per cent surviving 5 years. Advanced age, elevated aspartate transaminase and failure to respond to treatment were identified by multivariate regression analysis as adverse prognostic factors.
Cyclosporin associated demyelination following allogeneic bone marrow transplantation
Authors: Lind M. J. , McWilliam L. , Jip J. , Scarffe J. H. , Morgenstern G. R. , Chang J. 
Published: February 2007

AbstractNeurological complications associated with cyclosporin administration are well documented. However their histopathological basis are ill‐understood. We describe below a case of demyelination following cyclosporin administration to a patient following allogeneic bone marrow transplantation.
Treatment of acute myeloid leukemia in the elderly: A clinical dilemma
Authors: Copplestone J. A. , Smith A. G. , Osmond C. , Oscier D. G. , Hamblin T. J. 
Published: February 2007

AbstractFifty‐four patients representing all the cases of acute myeloid leukemia in patients aged over 60 years, presenting to three adjacent hospitals, were studied. Only 26 of the 54 patients were considered suitable for remission induction with intensive combination chemotherapy which produced seven complete remissions (CR) (26 per cent). Eighteen of the 54 patients survived longer than three months—11 of these had received remission induction chemotherapy (five CRs), two low dose cytarabine, one vincristine and vitamin A and four supportive treatment alone. By six months all the patients who had received supportive treatment had died.Patients who received intensive chemotherapy spent 77 per cent of the first 90 days in hospital and half died in hospital. Patients receiving differentiating agents or supportive care spent more time at home (37 per cent. 34 per cent of the first 90 days, respectively) but had shorter overall survival.Assessment of clinical characteristics in an attempt to predict response to treatment and survival indicated that poor performance status and the presence of infection were the most important factors. Analysis was limited by the statistically small number in the group.At present there is no reliable method of predicting which patients will respond well to treatment with intensive chemotherapy. The clinical dilemma is whether to treat more intensively to benefit a minority, or to use supportive treatment to allow more time to be spent at home albeit with a shorter overall survival.
Pulsed high dose oral prednisolone in relapsed or refractory multiple myeloma
Authors: Norfolk D. R. , Child J. A. 
Published: February 2007

AbstractSeventeen unselected patients with relapsed or refractory multiple myeloma were treated with oral prednisolone 60 mg per m2 for five consecutive days with nine‐day treatment‐free intervals. Of the fourteen patients who completed at least six courses of treatment there were five good responses (Chronic Leukemia–Myeloma Task Force Criteria), five partial responses and four failures. Median survival (all seventeen patients) was between 19 and 20 months. Eight patients achieved plateau phase (median duration 9 months). Eleven patients showed improved performance status and four became free of transfusion support. The commonest side‐effect was bacterial pulmonary infection. Peptic ulceration occurred in two patients despite prophylactic ranitidine. Other steroid‐related side‐effects were mild and well tolerated. This study provides further evidence for the efficacy of higher dose steroid regimens in relapsed or refractory myelomatosis and confirms that durable remissions may be achieved. Responders show a gratifying improvement in quality of life and are spared the many toxicities of combination cytotoxic chemotherapy. Further studies of high dose steroid regimens in first‐line therapy, especially in patients with bone marrow suppression, are clearly merited.
Is the Hodgkin cell A T‐ or B‐lymphocyte? recent evidence from geno‐ and immunophenotypic analysis and in‐vitro cell lines
Authors: Drexler Hans G. , Jones David B. , Diehl Volker , Minowada Jun 
Published: February 2007

AbstractThe cellular derivation of Hodgkin (H) and Reed‐Sternberg (RS) cells remains a controversial issue. A large body of conflicting results in the literature led to a variety of discordant speculations. The application of immunophenotyping, molecular biology and tissue culture provided additional means for investigations on the nature of H‐RS cells. Using immunoenzymatic staining with monoclonal antibodies (McAbs) at the single cell level, H‐RS cells from many, albeit not all cases, were shown to be positive for T‐ and/or B‐cell markers; none of the cases were labelled by anti‐myeloid or anti‐monocyte/macrophage McAbs. A common feature of the otherwise heterogeneous immunoprofile is the expression of activation and proliferation antigens besides HLA‐DR class II antigen and the X‐hapten.Clonal rearrangements of T‐cell receptor or immunoglobulin chain genes were found in 22 per cent of cases. The low frequency of positive samples might be due to the commonly low number of H‐RS cells in the total population which can lay below the threshold of sensitivity for genotypic analysis.Several cell lines containing H‐RS‐like cells have been established. These cell lines have geno‐ and immunophenotypic characteristics of T‐ or B‐cells, but lack properties of myeloid cells or monocytes/macrophages.In the absence of evidence in support of an origin from monocytes/macrophages or other non‐lymphoid cells the here reviewed data, which are based on geno‐ and immunophenotypic analysis of fresh and cultured H‐RS cells, provide a lead to a lymphoid derivation of H‐RS cells.
Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo‐radiotherapy?
Authors: Gianni A. M. , Bregni M. , Siena S. , Villa S. , Sciorelli G. A. , Ravagnani F. , Pellegris G. , Bonadonna G. 
Published: February 2007

AbstractThe role of high dose chemo‐radiotherapy with autologous bone marrow transplantation in the treatment of neoplasia remains to be clearly defined. Because of the iatrogenic morbidity, mortality and high cost of the supportive care required during the post‐transplantation period of prolonged marrow aplasia, intensive therapy remains a sophisticated procedure lacking proper evaluation in clinical trials. We report here that when autologous bone marrow cells are supplemented with a small number of peripheral blood nucleated cells collected after prior myelosuppressive chemotherapy, complete hematological recovery is so prompt that myeloid toxicity appears no longer the major limiting factor of high‐dose chemo‐radiotherapy. The increased therapeutic index made possible by the procedure will allow us to address the issue of whether intensive cytoreductive therapy can be useful as initial treatment of selected tumors with curative intent.
A phase 1a clinical trial of LYM‐1 monoclonal antibody serotherapy in patients with refractory b cell malignancies
Authors: Hu Eddie , Epstein Alan L. , Naeve Gregory S. , Gill Indraini , Martin Sue , Sherrod Andy , Nichols Peter , Chen David , Mazumder Amitabha , Levine Alexandra M. 
Published: February 2007

AbstractTen patients with refractory B cell lymphomas were treated with weekly intravenous infusions of escalating doses of murine monoclonal antibody (MoAb) LYM‐1 over four weeks. LYM‐1 is a recently developed IgG2a murine MoAb that recognizes a polymorphic HLA‐Dr antigen on surfaces of normal and malignant B cells but does not bind to any other normal tissues. MoAb LYM‐1 has several advantages for serotherapy, since the antigen it recognizes is not shed from the cell surface and does not modulate in response to MoAb therapy. Furthermore, in vitro studies have indicated significant anti‐tumour activity against lymphoma cell lines. In the current trial, dose‐dependent levels of free LYM‐1 were detected in the serum of all patients, but penetration of extravascular tumour tissues was poor. No significant toxicity or human anti‐mouse antibody responses were observed in any patient. Clinical responses were minor and appeared to correlate with the number of infiltrating T cells seen in the initial lymphoma specimens. LYM‐1 appears to be well‐tolerated and has demonstrated several potential advantages as a therapeutic agent in patients with lymphoma. The mechanism of anti‐tumour effect and plans for further clinical studies are discussed.
Terminal transferase positive acute myeloid leukemia: Immunophenotypic characterization and response to induction therapy
Authors: Coco Francesco Lo , Lopez Manuela , Pasqualetti Daniela , Montefusco Enrico , Cafolla Arturo , Monarca Bruno , Sgadari Cecilia , De Rossi Giulio 
Published: February 2007

AbstractA quantitative evaluation of terminal deoxynucleotidyl transferase (TdT) was performed using a highly sensitive enzyme immunoassay (EIA) in 72 previously untreated patients with acute myeloid leukemia (AML). Biological analysis of the leukemic cells included in all cases cytochemistry, search for Ph' chromosome and immunophenotyping with both anti‐lymphoid and anti‐myeloid monoclonal antibodies (MoAbs). Thirteen AML cases (18 per cent) were considered TdT + by EIA. According to the FAB classification, almost all of them (12 out of 13) were within the M1 and M2 subgroups. A mixed lymphoid‐myeloid phenotype was observed in one of the 13 TdT + cases, while in none of the others were lymphoid features detected. Nine of the 10 EIA TdT + cases studied in parallel were TdT positive with the conventional immunofluorescence assay. All patients received standard protocol chemotherapy and in 61 (13 TdT +, 48 TdT − ) the response to induction treatment was analysable. Only 3/13 TdT + patients (23 per cent) achieved a complete remission (CR), while in the TdT – group 38 patients had a CR (79 per cent) and 10 were resistant (p<0.01). It is suggested that the incidence, biological interest and prognostic significance of TdT + AML should encourage the routine and more accurate search for this marker in all patients with AML.
Peripheral T‐cell lymphoma presenting as hemophagocytic syndrome
Authors: Chan Eric Y. T. , Pi David , Chan George T. C. , Todd David , Ho Faith C. S. 
Published: February 2007

AbstractThree patients with peripheral T‐cell lymphoma presenting with pyrexia, wasting, hepatosplenomegaly and pancytopenia in the absence of myelophthisic lymphomatous involvement are reported. Early in the course of the disease when there was no significant lymphadenopathy, these cases created enormous diagnostic confusion. Although the clinical features were suggestive of malignant histiocytosis (MH), marrow findings showed phagocytic histiocytes which did not appear atypical, and the criteria for diagnosis of MH could not be satisfied. Lymph node enlargement was detected only after 14, 5, and 8 weeks from the onset of symptoms, and the diagnosis of T‐lymphoma was then made on lymph node biopsies. Treatment with multiple agent chemotherapy was attempted. Two patients died 3 days and 11 weeks after treatment was started and the third was lost to follow‐up. In contrast with most of the cases reported in the literature, our cases show that a reactive hemophagocytic syndrome can be an early and prominent manifestation of an underlying T‐cell lymphoma. Differentiation from other causes of hemophagocytic syndrome can be difficult and lack of histological proof of malignancy in the initial stage often delays definitive diagnosis and treatment.
Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis
Authors: Meusers P. , Engelhard M. , Bartels H. , Binder T. , Fülle H. H. , Görg K. , Gunzer U. , Havemann K. , Kayser W. , König E. , König H. J. , Kuse R. , Löffler H. , Ludwig W.‐D. , Mainzer K. , Martin H. , Pralle H. , Schoppe W. D. , Staiger H. J. , Theml H. , Zurborn K. H. , Zwingers Th. , Lennert K. , Brittinger G. 
Published: February 2007

AbstractWithin a multicentre observation study on non‐Hodgkin lymphomas (NHL) diagnosed according to the Kiel classification advanced stages III and IV of centrocytic (CC) lymphoma exhibited the worst prognosis among lymphomas of low‐grade malignancy with a 5‐year survival probability of less than 10 per cent. Treatment had been solely expectative and palliative with treatment results showing a prognostic superiority of patients achieving partial and complete remissions over non‐responders. Therefore, a randomized multicentre study was initiated to compare the remission‐inducing potential of the COP regimen (Bagleyet al., 1972) with that of the more intensive adriamycin‐containing CHOP regimen (McKelveyet al., 1976).From 91 newly diagnosed CC lymphomas 63 fulfilled randomization criteria with 37 patients assigned to the COP regimen and 26 patients to the CHOP regimen. Between the COP‐ and CHOP‐treated patients no significant differences could be demonstrated with respect to initial clinical parameters, rate of complete (41 per cent versus 58 per cent) or partial remissions (43 per cent versus 31 per cent), median overall survival probability (32 versus 37 months), relapse‐free survival (10 versus 7 months) and rates of relapse (73 per cent versus 67 per cent) and death (57 per cent versus 50 per cent).It can be concluded that CC lymphoma is a typical lymphoma of low‐grade malignancy with its inability to reach stable remissions while the demonstration of identical survival probabilities for patients with complete and partial remissions constitutes a unique feature of this lymphoma entity. These observations prove advanced CC lymphoma to represent an incurable neoplastic disease under conventional therapeutic approaches.
Primary intestinal lymphoma of Ki‐1 large cell anaplastic type with mesenteric lymph node and spleen involvement in a renal transplant recipient
Authors: Audouin J. , Le Tourneau A. , Diebold J. , Reynes M. , Tabbah I. , Bernadou A. 
Published: February 2007

AbstractA laparotomy performed for an occlusive syndrome, disclosed the presence of an ileal lymphoma in a renal graft recipient, 17 years after a first renal transplant. Mesenteric lymph node and spleen involvement were associated. The morphology of the large cells, the type of infiltration of the lymph node simulating metastatic carcinoma or malignant histiocytosis were highly suggestive of a new type of high grade malignancy lymphoma recently described which is called ‘large cell anaplastic ML’. The immunolabelling study confirmed this diagnosis, demonstrating the following phenotype CD4, CD25 (TAC), CD30 (Ki‐1), OKT 9 (transferrin receptor), EMA and HLA DR positivity. The tumour cells were negative for the other T, B and histiomono‐cytic markers. This case, of a large cell anaplastic Ki‐1 positive lymphoma, expressing CD4, in a renal graft recipient shows that high grade ML in such patients are not all of the B cell type.
LONG‐TERM EFFECTS OF PARENTERAL DICHLOROMETHYLENE BISPHOSPHONATE (CL2MBP) ON BONE DISEASE OF MYELOMA PATIENTS TREATED WITH CHEMOTHERAPY
Authors: Merlini Giampaolo , Parrinello Giuseppe Attardo , Piccinini Lino , Crema Francesca , Fiorentini Maria L. , Riccardi Alberto , Pavesi Franco , Novazzi Francesco , Silingardi Vittorio , Ascari Edoardo 
Published: February 2007

AbstractData on the long‐term treatment of myeloma bone disease with bisphosphonates are scanty. In a prospective pilot trial we evaluated the effect of long‐term parenteral administration of dichloromethylene bisphosphonate (Clodronate), in addition to standard chemotherapy, in 30 patients with active myeloma bone disease. Patients were treated with a mean of 4 courses (range 2–8) of Clodronate: 300 mg/day i.v. for seven days followed by 100 mg/day i.m. for 10 days, administered at a mean interval of 4 months (range 3–6). The median follow‐up was 24 months (range 8–36). Clodronate reduced bone pain rapidly and significantly, and reduced the mean values of the biochemical indices of bone resorption to within normal limits; these effects were maintained throughout the follow‐up. In three hypercalcemic episodes serum calcium became normal after 2–5 days of treatment with Clodronate. No toxic or side effects were noticed. The occurrence of skeletal morbidity in patients treated with Clodronate was compared with that observed in the control group of myeloma patients treated with chemotherapy only: Clodronate provided a significant reduction (p < 0.001) in severe bone pain as well as in the incidence of new osteolytic lesions and pathological fractures (p<0.001). Supportive Clodronate therapy contributes significantly in controlling the progression of myeloma bone disease.
Significance of common acute lymphoblastic leukemia antigen (cALLA) positive cells in bone marrow of children off therapy in complete remission
Authors: Self S. E. , Morgan S. , Grush O. , La Via M. F. 
Published: February 2007

AbstractBone marrows from 21 children with acute lymphoblastic leukemia in complete remission (CR) and off therapy for 14 months to 10 years were examined by flow cytometry with a panel of monoclonal antibodies. Significant percentages of cALLA + cells of low fluorescence intensity were present up to 9 years after CR. These results emphasize the need to interpret flow cytometry results in light of the findings that low intensity cALLA + cells represent a normal population of immature, non‐malignant lymphoid cells.
Normal B cell compartment in chronic lymphatic leukemia
Authors: Pluta A. , Górski A. , Nowaczyk M. , Modlińska M. 
Published: February 2007

AbstractIn contrast to normal B lymphocytes, CLL cells express CD5 antigen believed to be a T cell marker. We have assessed normal and malignant B cell compartments in CLL patients with the aid of two‐colour immunofluorescence techniques (CD5‐TRITC, DR‐FITC). No clear correlation was found between progression of disease and parameters studied. However, there was a tendency for a diminution of normal B cells in advanced stages of disease.